- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05200364
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a Phase 1, open-label, multicenter, dose escalation study to assess preliminary efficacy for STRO-002 combined with bevacizumab in patients with advanced ovarian cancer that is refractory or has relapsed after standard available therapy. Fallopian tube and primary peritoneal cancers are treated in the same manner as epithelial ovarian cancers and are thus included in this study.
The dosing regimen will include bevacizumab administered at the labeled dose of 15 mg/kg IV q 3 weeks given together with STRO-002 at increasing dose levels administered IV q 3 weeks. The RP2D of STRO-002 given with bevacizumab 15 mg/kg q 3 weeks will be determined by dose escalation.
Dose expansion will enroll approximately 40 subjects with advanced relapsed ovarian cancer treated with STRO-002 plus bevacizumab at the RP2D determined in dose escalation. Subjects in the dose expansion portion of the study will be required at screening to submit both archival tumor tissue (if available and available tissue has adequate tumor) and tumor tissue from a biopsy done during screening to the central laboratory for analysis of FOLRα expression, both prior to enrollment in the study.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Jason Kuriakose, MBA
- Phone Number: 650-676-4642
- Email: STRO-002ClinDev@sutrobio.com
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- Recruiting
- University of South Florida,
-
Contact:
- Marlene Martin
- Phone Number: 813-844-5012
- Email: marlenecmartin@tgh.org
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- University of Pennsylvania
-
Contact:
- Christine Yang
- Phone Number: 215-349-8930
- Email: christine.yang@pennmedicine.upenn.edu
-
Principal Investigator:
- Lanie Martin, MD
-
Philadelphia, Pennsylvania, United States, 19017
- Recruiting
- Thomas Jefferson University
-
Contact:
- Phone Number: 215-586-0199
- Email: askphase1@jefferson.edu
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Recruiting
- Tennessee Oncology
-
Contact:
- Phone Number: 615-320-5090
- Email: DDUreferrals@sarahcannon.com
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Recruiting
- Virginia Cancer Specialists
-
Contact:
- Alexander Spira, MD
- Phone Number: 703-280-5390
- Email: alexander.spira@usoncology.com
-
Contact:
- Carrie Friedman
- Phone Number: (703) 280-5390
- Email: carrie.friedman@usoncology.com
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Recruiting
- Medical College of Wisconsin
-
Contact:
- Matthew Lasowski
- Phone Number: 414-805-8594
- Email: mlasowski@mcw.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years.
- ECOG 0-1
- Life expectancy > 3 months
- High Grade serous epithelial ovarian cancer (EOC), fallopian tube or primary peritoneal cancer with pathology report documentation of tumor type.
- At least one measurable target lesion per RECIST v1.1.
Tumor tissue for FolRα expression testing prior to enrollment.
- For dose escalation: tissue may be from either archival tumor tissue or from a biopsy performed during screening.
- For dose expansion part of the study, tissue from both archival tumor tissue and a biopsy performed during screening is required.
Adequate bone marrow function defined as:
- Absolute neutrophil count (ANC) ≥1500/μL
- Hemoglobin ≥ 9g/dL
- Platelet count ≥ 100 x 10^3/μL
Adequate liver function defined as:
- ALT and AST < 2.5 x ULN
- ALP < 2.5 x ULN
- Bilirubin < 1.5 x ULN
Adequate renal function defined as serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) > 40 mL/min.
Subjects enrolling into Dose Escalation must also meet the following inclusion criteria:
Relapsed and/or PD on last treatment regimen and one of the following:
- Primary Platinum refractory and received no more than 1 prior regimen
- Primary platinum resistant and received no more than 4 prior regimens
Platinum sensitive and all of the following:
- received at least 2 platinum-based therapies or received 1 platinum and 1 non-platinum based therapy (if unable to receive a second platinum regimen due to toxicity) or received at least 1 platinum-based therapy (if the regimen contained a PARP inhibitor given as maintenance treatment)
- received no more than 1 additional regimen after becoming platinum resistant
- received no more than 4 prior regimens
Subjects enrolling into Part 2, Dose Expansion must also meet the following inclusion criteria:
Relapsed and/or PD on last treatment regimen and one of the following:
- Platinum resistant and received no more than 4 prior regimens
Platinum sensitive and
- received at least 2 platinum-based therapies or received 1 platinum and 1 non-platinum based therapy (if unable to receive a second platinum regimen due to toxicity) or received at least 1 platinum-based therapy (if the regimen contained a PARP inhibitor given as maintenance treatment)
- received no more than 1 additional regimen after becoming platinum resistant
- received no more than 4 prior regimens
Exclusion Criteria:
- Low grade ovarian carcinoma (Grade 1).
- Clear cell, mucinous, endometrioid, sarcomatous, and mixed histology ovarian carcinomas, endometrial leiomyosarcoma, and endometrial stromal sarcomas.
- Prior treatment with an ADC with a tubulin inhibitor warhead.
- Prior treatment with other FolRα targeting agents unless approved by a Sutro medical monitor or designee.
- Subjects who are primary platinum-refractory during frontline treatment are excluded from the Expansion Cohort (Allowed in Dose Escalation if no more than 1 prior regimen).
- Greater than 4 prior lines of treatment (> 1 prior if primary platinum refractory).
- Any prior toxicity that required permanent discontinuation of bevacizumab or other contraindication to receive bevacizumab per institutional guidelines.
- Previous solid organ transplantation.
- Current signs/symptoms of bowel obstruction and/or signs/symptoms of or bowel obstruction within 3 months of initiation of study treatment.
- Grade ≥2 toxicity from prior anticancer therapy with the exception of Grade 2 alopecia or Grade 2 neuropathy.
- Uncontrolled hypertension
- Sensory or motor neuropathy Grade > 1 at screening prior to initiation of study treatment.
- Potentially fatal concurrent or recent malignancy. Subjects with past or current malignancy need to be discussed with the sponsor to determine eligibility.
- Chronic or ongoing active infection requiring systemic treatment.
- Ongoing immunosuppressive therapy, including systemic corticosteroids. Note: Physiologic replacement and use of topical or inhaled corticosteroids are allowed. Dexamethasone may be used to treat chemotherapy induced nausea per institutional guidelines.
- Clinically significant cardiac disease.
- History or clinical signs of meningeal or active central nervous system involvement.
- Known severe COPD or asthma
- Active pneumonitis within 6 months of initiating study treatment.
- History of stroke or history of significant cerebrovascular disease (i.e., transient ischemic attack) within 6 months of initiation of study treatment.
- History of pulmonary embolism or any Grade 3 thromboembolic event within 6 months of initiation of study treatment.
- Known human immunodeficiency virus seropositivity.
Active hepatitis B or hepatitis C and positive serology (unless due to vaccination or passive immunization due to immunoglobulin therapy) with the following exceptions:
- Subject has had HCV but received antiviral treatment and shows no detectible HCV viral DNA for 6 months prior to screening
- Subject has had HBV but is HBV surface antigen (HBsAg) and viral DNA negative at screening
- Subject has had HBV but received antiviral treatment and have undetectable viral DNA for 6 months prior to screening
- Concurrent participation in another therapeutic treatment trial
- Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease
- Females who are pregnant or breastfeeding, and all women of childbearing potential unwilling to use adequate barrier contraception while on treatment and for 16 weeks after last dose of STRO-002/bevacizumab and 6 months after the last dose of bevacizumab.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental :STRO-002 treatment in combination with Bevacizumab
Dose Escalation: STRO-002 at increasing dose levels plus bevacizumab at 15 mg/kg Dose Expansion: STRO-002 at RP2D plus bevacizumab at 15 mg/kg |
intravenous antibody drug conjugate
anti-VEGF agent
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1 - Safety and tolerability of STRO-002/bevacizumab as a combination therapy
Time Frame: From baseline through end of study (approximately 24 months)
|
Incidence and severity of adverse events (AEs) and clinical laboratory abnormalities observed across STRO-002/bevacizumab dose levels.
Incidence of dose-limiting toxicities (DLTs) through Day 1-21 following administration of each initial STRO-002/bevacizumab dose.
|
From baseline through end of study (approximately 24 months)
|
Part 1 - Determine the recommended phase 2 dose (RP2D) of STRO-002/bevacizumab
Time Frame: From baseline through end of study (approximately 24 months)
|
Frequency of DLTs across STRO-002 dose levels
|
From baseline through end of study (approximately 24 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1 - Characterize the pharmacokinetics (PK) of STRO-002 by measuring the maximum plasma concentration (Cmax).
Time Frame: From baseline through end of study (approximately 24 months)
|
Measurement of maximum plasma concentration (Cmax) after the administration of STRO-002
|
From baseline through end of study (approximately 24 months)
|
Part 1 - Characterize the PK of STRO-002 by measuring the area under the plasma concentration versus time curve (AUC)
Time Frame: From baseline through end of study (approximately 24 months)
|
Measurement of AUC
|
From baseline through end of study (approximately 24 months)
|
Part 1 - Assess the formation of anti-drug antibodies (ADAs) to STRO-002 when administered with bevacizumab.
Time Frame: From baseline through end of study (approximately 24 months)
|
Circulating ADAs formed to STRO-002
|
From baseline through end of study (approximately 24 months)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Arturo Molina, MD, Sutro Biopharma
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Fallopian Tube Diseases
- Carcinoma
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Carcinoma, Ovarian Epithelial
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
Other Study ID Numbers
- STRO-002-GM2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovarian Cancer
-
Roswell Park Cancer InstituteCompletedFallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IIA Ovarian Cancer | Stage IIB Ovarian Cancer | Stage IIC Ovarian Cancer | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian Cancer | Stage IA Ovarian Cancer | Stage IB Ovarian Cancer | Stage IC... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedCancer Survivor | Stage IIIA Ovarian Epithelial Cancer | Stage IIIB Ovarian Epithelial Cancer | Stage IIIC Ovarian Epithelial Cancer | Stage IIA Ovarian Epithelial Cancer | Stage IIB Ovarian Epithelial Cancer | Stage IIC Ovarian Epithelial Cancer | Stage IA Ovarian Epithelial Cancer | Stage IB Ovarian... and other conditionsUnited States
-
Massachusetts General HospitalJohns Hopkins University; M.D. Anderson Cancer Center; National Cancer Institute... and other collaboratorsRecruitingOvarian Neoplasms | Fallopian Tube Neoplasms | Stage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedStage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian... and other conditionsUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedCaregiver | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Eve RodlerNot yet recruitingBreast Cancer | Ovarian Cancer | Breast Neoplasm | Breast Carcinoma | Breast Cancer Stage IV | Breast Cancer Stage I | Breast Cancer Stage II | Invasive Breast Cancer | Cancer, Breast | Breast Cancer Stage III | Ovary Cancer | Malignant Tumor of Breast | Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Ovarian Cancer... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Centre Leon BerardCancer Côte d'or registry; Cancer Calvados registryUnknownOvarian Epithelial CancerFrance
Clinical Trials on STRO-002
-
Tasly Pharmaceutical Group Co., LtdSutro Biopharma, Inc.Recruiting
-
Sutro Biopharma, Inc.RecruitingOvarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Ovarian Carcinoma | Endometrioid Adenocarcinoma | Ovary Cancer | Primary Peritoneal CarcinomaUnited States, Spain
-
BioNova Pharmaceuticals (Shanghai) LTD.TerminatedFollicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell LymphomaChina
-
Avalo Therapeutics, Inc.CompletedNon-Eosinophilic AsthmaUnited States
-
Aevi Genomic Medicine, LLC, a Cerecor companyCompletedAcute Lung Injury | ARDS | COVID-19 PneumoniaUnited States
-
Sutro Biopharma, Inc.Active, not recruitingFollicular Lymphoma | B-cell Lymphoma | Multiple Myeloma | Mantle Cell Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Indolent Lymphoma | B Cells--TumorsUnited States
-
Avalo Therapeutics, Inc.TerminatedCrohn Disease | Ulcerative ColitisUnited States
-
Vyluma, Inc.Syneos HealthActive, not recruitingMyopiaUnited States, Hungary, Ireland, Netherlands, Spain, United Kingdom
-
BiocadRecruitingStudy of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)Hemophilia BRussian Federation
-
PMG Pharm Co., LtdRecruitingKnee OsteoarthritisKorea, Republic of